<?xml version='1.0' encoding='utf-8'?>
<document id="12065439"><sentence text="In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450." /><sentence text="E2101 or N-methyl-[1-[1-(2-fluorophenethyl)piperidine-4-yl]-1H-indol-6-yl] acetamide, an antagonist of 5-hydroxytryptamine receptor subtypes 1A and 2, is currently under development for the potential treatment of skeletal muscle associated spasticity"><entity charOffset="9-84" id="DDI-PubMed.12065439.s2.e0" text="N-methyl-[1-[1-(2-fluorophenethyl)piperidine-4-yl]-1H-indol-6-yl] acetamide" /><entity charOffset="103-122" id="DDI-PubMed.12065439.s2.e1" text="5-hydroxytryptamine" /><pair ddi="false" e1="DDI-PubMed.12065439.s2.e0" e2="DDI-PubMed.12065439.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12065439.s2.e0" e2="DDI-PubMed.12065439.s2.e1" /></sentence><sentence text=" Here we characterized the in vitro metabolism of E2101 using human liver enzymes including human liver microsomal preparations, human liver S9 fractions, and individual forms of recombinant cytochromes P450 (P450s)" /><sentence text=" Our results showed that E2101 was metabolized by P450s to form monohydroxylated (M1 and M2), dihydroxylated (M3), and N-dealkylated metabolites (M4)" /><sentence text=" The structures of these major microsomal metabolites were proposed based on LC/MS/MS analyses" /><sentence text=" All four metabolites, M1-M4, were formed by CYP3A4" /><sentence text=" Metabolites, M1, M2, and M4, were also formed by CYP2C19 and M2 and M3 by CYP2D6" /><sentence text=" The potential P450 inhibition and induction of E2101 were also evaluated" /><sentence text=" E2101 was determined to be a competitive inhibitor of CYP2C19 and CYP2D6 with K(i) of 15 and 48 microM, respectively, as determined by both Dixon plots and simultaneously nonlinear regression analyses" /><sentence text=" Induction of major P450 expression was not detected immunochemically after 72-h exposure to 10 or 50 microM E2101 in primary hepatocyte cultures obtained from three subjects" /><sentence text=" Taken together, E2101 is expected to metabolically interact with major human P450 enzymes including CYP2C19, CYP2D6, and CYP3A4, and a low risk of drug-drug interaction would be anticipated in clinical studies" /><sentence text="" /></document>